gene	chromosome	start_position	end_position	reference_allele	alternate_allele	cdna_change	protein_change	variant_annotation	exon	rsid	pathogenic	disease	context	oncotree_term	oncotree_code	therapy_name	therapy_strategy	therapy_type	therapy_sensitivity	therapy_resistance	favorable_prognosis	adverse_event_risk	predictive_implication	description	preferred_assertion	source_type	citation	url	doi	pmid	nct	last_updated
ATM												Any solid tumor		Any solid tumor		Radiation therapy	Radiation	Radiation therapy				1	Clinical evidence	Germline variants in ATM and other DNA repair genes have been described in patients experiencing extreme normal tissue toxicity from radiation.		Journal	"Pollard JM, Gatti RA. Clinical Radiation Sensitivity With DNA Repair Disorders: An Overview International Journal of Radiation Oncology*Biology*Physics. 2009; 74(5):1323-1331."	https://doi.org/10.1016/j.ijrobp.2009.02.057	10.1016/j.ijrobp.2009.02.057	19616740		9/12/19
ATM											1	Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD						0		Clinical evidence	Pathogenic germline variants in ATM may increase risk of acquiring CRC. Germline pathogenic variants in ATM were enriched in several large cohorts of CRC patients when the frequency of multiple DNA-repair genes was compared to that of ancestry-matched healthy patients.		Journal	"AlDubayan SH, Giannakis M, Moore ND, et al. Inherited DNA-Repair Defects in Colorectal Cancer The American Journal of Human Genetics. 2018; 102(3):401-414."	https://doi.org/10.1016/j.ajhg.2018.01.018	10.1016/j.ajhg.2018.01.018	29478780		4/16/19
ATM	11	108128198	108128198	T	G	c.2251-10T>G				rs730881346	1	Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD	Olaparib	PARP inhibition	Targeted therapy	1				Preclinical	"SK-CO-1 cells are homozygous for ATM c.2251-10>T, lack ATM protein expression, and are sensitive to the PARP inhibitor olaparib."		Journal	"Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196."	https://doi.org/10.1016/j.tranon.2017.01.007	10.1016/j.tranon.2017.01.007	28182994		8/15/19
BARD1												Ovarian Cancer	Primary	"Ovarian Cancer, Other"	OOVC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
BARD1												Ovarian Cancer	Primary	"Ovarian Cancer, Other"	OOVC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
BARD1												Peritoneal Carcinoma	Primary	Peritoneal Mesothelioma	PEMESO						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
BARD1												Peritoneal Carcinoma	Primary	Peritoneal Mesothelioma	PEMESO						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
BARD1												Fallopian Tube Carcinoma	Primary	Serous Ovarian Cancer	SOC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
BARD1												Fallopian Tube Carcinoma	Primary	Serous Ovarian Cancer	SOC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
BRCA1											1	Ovarian Cancer	"Advanced, treated with three or more prior lines of chemotherapy"	Ovarian Epithelial Tumor	OVT	Niraparib	PARP inhibition	Targeted therapy	1				FDA-Approved	"The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy."		FDA	"GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf				10/15/20
BRCA1											1	Fallopian tube cancer	Treated with three or more prior lines of chemotherapy	High-Grade Serous Fallopian Tube Cancer	HGSFT	Niraparib	PARP inhibition	Targeted therapy	1				FDA-Approved	"The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy."		FDA	"GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf				10/15/20
BRCA1											1	Peritoneal cancer	"Primary, treated with three or more prior lines of chemotherapy"	Peritoneal Serous Carcinoma	PSEC	Niraparib	PARP inhibition	Targeted therapy	1				FDA-Approved	"The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy."		FDA	"GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf				10/15/20
BRCA1											1	Breast Cancer	"HER2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting"	Invasive Breast Carcinoma	BRCA	Olaparib	PARP inhibition	Targeted therapy	1				FDA-Approved	"The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting."		FDA	"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf				11/12/20
BRCA1											1	Epithelial ovarian cancer	"Advanced, treated with three or more prior lines of chemotherapy"	Ovarian Epithelial Tumor	OVT	Olaparib	PARP inhibition	Targeted therapy	1				FDA-Approved	"The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. "		FDA	"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf			NCT01844986	11/12/20
BRCA1											1	Fallopian tube cancer	"Advanced, treated with three or more prior lines of chemotherapy"	High-Grade Serous Fallopian Tube Cancer	HGSFT	Olaparib	PARP inhibition	Targeted therapy	1				FDA-Approved	"The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. "		FDA	"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf			NCT01844986	11/12/20
BRCA1											1	Peritoneal cancer	Primary	Peritoneal Serous Carcinoma	PSEC	Olaparib	PARP inhibition	Targeted therapy	1				FDA-Approved	"The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. "		FDA	"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf			NCT01844986	11/12/20
BRCA1											1	Ovarian Cancer		"Ovarian Cancer, Other"	OOVC	Olaparib	PARP inhibition	Targeted therapy	1				Guideline	"Patients with chemotherapy-refractory ovarian cancer have higher response rates to PARP inhibitor therapy in the presence of BRCA1 and BRCA2 mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations."		Guideline	"National Comprehensive Cancer Network. Ovarian Cancer NCCN Evidence Blocks (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf			NCT01844986	3/7/19
BRCA1											1	Ovarian Cancer		"Ovarian Cancer, Other"	OOVC	Pazopanib	FGFR inhibition + KIT inhibition + PDGFR inhibition + VEGF/VEGFR inhibition	Targeted therapy	1				Guideline	Pazopanib may increase PFS in patients whose disease does not progress following first-line treatment.		Guideline	"National Comprehensive Cancer Network. Ovarian Cancer NCCN Evidence Blocks (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf		26740259		11/3/17
BRCA1												Pancreatic Cancer		Pancreatic Adenocarcinoma	PAAD	Platinum	Platinum-based chemotherapy	Chemotherapy	1				Clinical evidence	"When present alongside genomic instability, defined by a large number of structural variation events, the inactivation of DNA maintenance genes (BRCA1, BRCA2, PALB2) was associated with increased sensitivity to platinum therapy in pancreatic cancer patients. "		Journal	"Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495-501."	https://doi.org/10.1038/nature14169	10.1038/nature14169	25719666		3/7/19
BRCA1											1	Invasive Breast Cancer	"HER2-negative, recurrent or metastatic"	Invasive Breast Carcinoma	BRCA	Olaparib	PARP inhibition	Targeted therapy	1				Guideline	PARP inhibitors are recommended for patients with recurrent or stage IV disease with HER2-negative tumors with germline BRCA1/2 variants.		Guideline	"National Comprehensive Cancer Network. Invasive Breast Cancer NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf. Accessed August 10, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf				8/10/19
BRCA1											1	Invasive Breast Cancer	"HER2-negative, recurrent or metastatic"	Invasive Breast Carcinoma	BRCA	Talazoparib	PARP inhibition	Targeted therapy	1				Guideline	PARP inhibitors are recommended for patients with recurrent or stage IV disease with HER2-negative tumors with germline BRCA1/2 variants.		Guideline	"National Comprehensive Cancer Network. Invasive Breast Cancer NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf. Accessed August 10, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf				8/10/19
BRCA1											1	Invasive Breast Cancer	"Triple-negative, recurrent or metastatic"	Invasive Breast Carcinoma	BRCA	Carboplatin	Platinum-based chemotherapy	Chemotherapy	1				Guideline	Platinum chemotherapies are recommended for patients with recurrent or stage IV disease with triple-negative tumors and germline BRCA 1/2 variants.		Guideline	"National Comprehensive Cancer Network. Invasive Breast Cancer NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf. Accessed August 10, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf				8/10/19
BRCA1											1	Invasive Breast Cancer	"Triple-negative, recurrent or metastatic"	Invasive Breast Carcinoma	BRCA	Cisplatin	Platinum-based chemotherapy	Chemotherapy	1				Guideline	Platinum chemotherapies are recommended for patients with recurrent or stage IV disease with triple-negative tumors and germline BRCA 1/2 variants.		Guideline	"National Comprehensive Cancer Network. Invasive Breast Cancer NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf. Accessed August 10, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf				8/10/19
BRCA1											1	Breast Cancer	HER2-negative locally advanced or metastatic	Invasive Breast Carcinoma	BRCA	Talazoparib	PARP inhibition	Targeted therapy	1				FDA-Approved	The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative localy advanced or metastatic breast cancer. 		FDA	"Talzenna [package insert]. New York, NY: Pfizer Inc.; 2018."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211651s000lbl.pdf			NCT01945775	3/23/20
BRCA1											1	Ovarian Cancer	"Advanced, treated with three or more prior lines of chemotherapy"	Ovarian Epithelial Tumor	OVT	Niraparib	PARP inhibition	Targeted therapy	1				FDA-Approved	"The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy."		FDA	"GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf				10/15/20
BRCA1											1	Fallopian tube cancer	Treated with three or more prior lines of chemotherapy	High-Grade Serous Fallopian Tube Cancer	HGSFT	Niraparib	PARP inhibition	Targeted therapy	1				FDA-Approved	"The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy."		FDA	"GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf				10/15/20
BRCA1											1	Peritoneal cancer	"Primary, treated with three or more prior lines of chemotherapy"	Peritoneal Serous Carcinoma	PSEC	Niraparib	PARP inhibition	Targeted therapy	1				FDA-Approved	"The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy."		FDA	"GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf				10/15/20
BRCA1											1	Prostate Cancer	Metastatic castration resistant prostate cancer	Prostate Adenocarcinoma	PRAD	Olaparib	PARP inhibition	Targeted therapy	1				FDA-Approved	"The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone."		FDA	"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf				10/22/20
BRCA2											1	Invasive Breast Cancer	"HER2-negative, recurrent or metastatic"	Invasive Breast Carcinoma	BRCA	Olaparib	PARP inhibition	Targeted therapy	1				Guideline	PARP inhibitors are recommended for patients with recurrent or stage IV disease that are also HER2-negative tumors with germline BRCA1/2 variants.		Guideline	"National Comprehensive Cancer Network. Invasive Breast Cancer NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf. Accessed August 10, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf				8/10/19
BRCA2											1	Invasive Breast Cancer	"HER2-negative, recurrent or metastatic"	Invasive Breast Carcinoma	BRCA	Talazoparib	PARP inhibition	Targeted therapy	1				Guideline	PARP inhibitors are recommended for patients with recurrent or stage IV disease that are also HER2-negative tumors with germline BRCA1/2 variants.		Guideline	"National Comprehensive Cancer Network. Invasive Breast Cancer NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf. Accessed August 10, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf				8/10/19
BRCA2											1	Invasive Breast Cancer	"Triple-negative, recurrent or metastatic"	Invasive Breast Carcinoma	BRCA	Carboplatin	Platinum-based chemotherapy	Chemotherapy	1				Guideline	Platinum chemotherapies are recommended for patients with recurrent or stage IV disease with triple-negative tumors and germline BRCA 1/2 variants.		Guideline	"National Comprehensive Cancer Network. Invasive Breast Cancer NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf. Accessed August 10, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf				8/10/19
BRCA2											1	Invasive Breast Cancer	"Triple-negative, recurrent or metastatic"	Invasive Breast Carcinoma	BRCA	Cisplatin	Platinum-based chemotherapy	Chemotherapy	1				Guideline	Platinum chemotherapies are recommended for patients with recurrent or stage IV disease with triple-negative tumors and germline BRCA 1/2 variants.		Guideline	"National Comprehensive Cancer Network. Invasive Breast Cancer NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf. Accessed August 10, 2019."	https://www.nccn.org/professionals/physician_gls/pdf/breast_blocks.pdf				8/10/19
BRCA2											1	Breast Cancer	HER2-negative locally advanced or metastatic	Invasive Breast Carcinoma	BRCA	Talazoparib	PARP inhibition	Targeted therapy	1				FDA-Approved	The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative localy advanced or metastatic breast cancer. 		FDA	"Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211651s006lbl.pdf. Revised October 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211651s006lbl.pdf			NCT01945775	11/12/20
BRCA2											1	Breast Cancer	"HER2-negative, metastatic, treated with chemotherapy in neoadjuvant, adjuvant, or metastatic setting"	Invasive Breast Carcinoma	BRCA	Olaparib	PARP inhibition	Targeted therapy	1				FDA-Approved	"The U.S. Food and Drug Administration (FDA) granted approval for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer who have been treated with chemotherapy either in the neoadjuvant, adjuvant, or metastatic setting."		FDA	"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf				11/12/20
BRCA2											1	Ovarian Cancer	"Advanced, treated with three or more prior lines of chemotherapy"	Ovarian Epithelial Tumor	OVT	Niraparib	PARP inhibition	Targeted therapy	1				FDA-Approved	"The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy."		FDA	"GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf				10/15/20
BRCA2											1	Fallopian tube cancer	Treated with three or more prior lines of chemotherapy	High-Grade Serous Fallopian Tube Cancer	HGSFT	Niraparib	PARP inhibition	Targeted therapy	1				FDA-Approved	"The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy."		FDA	"GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf				10/15/20
BRCA2											1	Peritoneal cancer	"Primary, treated with three or more prior lines of chemotherapy"	Peritoneal Serous Carcinoma	PSEC	Niraparib	PARP inhibition	Targeted therapy	1				FDA-Approved	"The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy."		FDA	"GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf				10/15/20
BRCA2											1	Epithelial ovarian cancer	"Advanced, treated with three or more prior lines of chemotherapy"	Ovarian Epithelial Tumor	OVT	Olaparib	PARP inhibition	Targeted therapy	1				FDA-Approved	"The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. "		FDA	"AstraZeneca Pharmaceuticals LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf			NCT01844986	11/12/20
BRCA2											1	Fallopian tube cancer	"Advanced, treated with three or more prior lines of chemotherapy"	High-Grade Serous Fallopian Tube Cancer	HGSFT	Olaparib	PARP inhibition	Targeted therapy	1				FDA-Approved	"The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. "		FDA	"AstraZeneca Pharmaceuticals LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf			NCT01844986	11/12/20
BRCA2											1	Peritoneal cancer	Primary	Peritoneal Serous Carcinoma	PSEC	Olaparib	PARP inhibition	Targeted therapy	1				FDA-Approved	"The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. "		FDA	"AstraZeneca Pharmaceuticals LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf			NCT01844986	11/12/20
BRCA2												Ovarian Cancer		"Ovarian Cancer, Other"	OOVC	Olaparib	PARP inhibition	Targeted therapy	1				Guideline	"Patients with chemotherapy-refractory ovarian cancer have higher response rates to PARP inhibitor therapy in the presence of BRCA1 and BRCA2 mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations."		Guideline	"National Comprehensive Cancer Network. Ovarian Cancer NCCN Evidence Blocks (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf				11/3/17
BRCA2												Ovarian Cancer		"Ovarian Cancer, Other"	OOVC	Olaparib	PARP inhibition	Targeted therapy	1				Guideline	"Patients with chemotherapy-refractory ovarian cancer have higher response rates to PARP inhibitor therapy in the presence of BRCA1 and BRCA2 mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations."		Guideline	"National Comprehensive Cancer Network. Ovarian Cancer NCCN Evidence Blocks (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf				11/3/17
BRCA2												Ovarian Cancer		"Ovarian Cancer, Other"	OOVC	Pazopanib	FGFR inhibition + KIT inhibition + PDGFR inhibition + VEGF/VEGFR inhibition	Targeted therapy	1				Guideline	Pazopanib may increase PFS in patients whose disease does not progress following first-line treatment.		Guideline	"National Comprehensive Cancer Network. Ovarian Cancer NCCN Evidence Blocks (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/ovarian_blocks.pdf		26740259		11/3/17
BRCA2												Prostate Cancer		Prostate Adenocarcinoma	PRAD	Olaparib	PARP inhibition	Targeted therapy	1				Clinical trial	"Patients with chemotherapy-refractory prostate cancer have higher response rates to PARP inhibitor therapy in the presence of DNA repair mutations, particularly concomittant with platinum-sensitive disease. Platinum-resistant disease partially abrogates olaparib sensitvity in the setting of BRCA1 and BRCA2 mutations."		Journal	"Mateo J, Carreira S, Sandhu S, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med. 2015;373(18):1697-708."	https://doi.org/10.1056/NEJMoa1506859	10.1056/NEJMoa1506859	26510020	NCT01682772	11/3/17
BRCA2												Pancreatic Cancer		Pancreatic Adenocarcinoma	PAAD	Platinum	Platinum-based chemotherapy	Chemotherapy	1				Clinical evidence	"When present alongside genomic instability, defined by a large number of structural variation events, the inactivation of DNA maintenance genes (BRCA1, BRCA2, PALB2) was associated with increased sensitivity to platinum therapy in pancreatic cancer patients. "		Journal	"Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495-501."	https://doi.org/10.1038/nature14169	10.1038/nature14169	25719666		3/7/19
BRCA2											1	Prostate Cancer	Metastatic castration resistant prostate cancer	Prostate Adenocarcinoma	PRAD	Olaparib	PARP inhibition	Targeted therapy	1				FDA-Approved	"The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone."		FDA	"AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020."	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf				10/22/20
CHEK1												Ovarian Cancer	Primary	"Ovarian Cancer, Other"	OOVC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
CHEK1												Ovarian Cancer	Primary	"Ovarian Cancer, Other"	OOVC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
CHEK1												Peritoneal Carcinoma	Primary	Peritoneal Mesothelioma	PEMESO						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
CHEK1												Peritoneal Carcinoma	Primary	Peritoneal Mesothelioma	PEMESO						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
CHEK1												Fallopian Tube Carcinoma	Primary	Serous Ovarian Cancer	SOC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
CHEK1												Fallopian Tube Carcinoma	Primary	Serous Ovarian Cancer	SOC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
CHEK2												Ovarian Cancer	Primary	"Ovarian Cancer, Other"	OOVC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
CHEK2												Ovarian Cancer	Primary	"Ovarian Cancer, Other"	OOVC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
CHEK2												Peritoneal Carcinoma	Primary	Peritoneal Mesothelioma	PEMESO						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
CHEK2												Peritoneal Carcinoma	Primary	Peritoneal Mesothelioma	PEMESO						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
CHEK2												Fallopian Tube Carcinoma	Primary	Serous Ovarian Cancer	SOC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
CHEK2												Fallopian Tube Carcinoma	Primary	Serous Ovarian Cancer	SOC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
CHEK2											1	Testicular Germ Cell Tumors		Testicular Germ Cell Tumors	TGCT						0		Clinical evidence	"CHEK2 variants may increase risk of acquiring testicular germ cells tumors. Germline pathogenic mutations in CHEK2 were enriched in both discovery and validation cohorts of European men with TGCTs, compared to the ExAC Non-Finnish Europeans cohort of healthy patients."		Journal	"AlDubayan SH, Pyle LC, Gamulin M, et al. Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 ( ) With Susceptibility to Testicular Germ Cell Tumors JAMA Oncol. 2019; 5(4):514-."	https://doi.org/10.1001/jamaoncol.2018.6477	10.1001/jamaoncol.2018.6477	30676620		4/16/19
EPCAM												Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD						1		Guideline	"Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy."		Guideline	"National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf		20498393		11/3/17
IL12RB1	19	18194272	18194272	G	A	c.94C>T	p.Q32*	Nonsense	2	rs121434492		Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD						0		Clinical evidence	Mutation may indicate increased susceptibility to early-onset colorectal cancer.		Journal	"Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883."	https://doi.org/10.1038/ncomms11883	10.1038/ncomms11883	27329137		6/13/19
IL12RB1	19	18173082	18173082	G	A	c.1624C>T	p.Q542*	Nonsense	15	rs372833507		Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD						0		Clinical evidence	Mutation may indicate increased susceptibility to early-onset colorectal cancer.		Journal	"Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883."	https://doi.org/10.1038/ncomms11883	10.1038/ncomms11883	27329137		6/13/19
LIMK2	22	31672776	31672776	-	C	c.1719dup	p.G574Rfs*12	Frameshift	15	rs540206607		Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD						0		Clinical evidence	Mutation may indicate increased susceptibility to early-onset colorectal cancer.		Journal	"Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883."	https://doi.org/10.1038/ncomms11883	10.1038/ncomms11883	27329137		6/13/19
LIMK2	22	31672807	31672807	-	G	c.1742dup	p.C582Lfs*4	Frameshift	15			Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD						0		Clinical evidence	Mutation may indicate increased susceptibility to early-onset colorectal cancer.		Journal	"Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883."	https://doi.org/10.1038/ncomms11883	10.1038/ncomms11883	27329137		6/13/19
LIMK2	22	31673114	31673114	-	A	c.2049_2050insA	p.G684Tfs*16	Frameshift	15			Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD						0		Clinical evidence	Mutation may indicate increased susceptibility to early-onset colorectal cancer.		Journal	"Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883."	https://doi.org/10.1038/ncomms11883	10.1038/ncomms11883	27329137		6/13/19
MLH1												Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD						1		Guideline	"Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy."		Guideline	"National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf		20498393		11/3/17
MLH3												Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	1				Clinical evidence	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.		Journal	"Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20."	https://doi.org/10.1056/NEJMoa1500596	10.1056/NEJMoa1500596	26028255	NCT01876511	2/4/19
MRE11	11	94180442	94180442	G	A	c.1726C>T	p.R576*	Nonsense	15	rs774277300		Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD						0		Clinical evidence	Mutation may indicate increased susceptibility to early-onset colorectal cancer.		Journal	"Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883."	https://doi.org/10.1038/ncomms11883	10.1038/ncomms11883	27329137		6/13/19
MRE11	11	94201010	94201011	C	-	c.1066del	p.H356Tfs*34	Frameshift	10			Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD						0		Clinical evidence	Mutation may indicate increased susceptibility to early-onset colorectal cancer.		Journal	"Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883."	https://doi.org/10.1038/ncomms11883	10.1038/ncomms11883	27329137		6/13/19
MRE11	11	94224125	94224137			c.21-6_26del	p.L7fs*18	Frameshift	3	rs587780138		Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD						0		Clinical evidence	Mutation may indicate increased susceptibility to early-onset colorectal cancer.		Journal	"Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883."	https://doi.org/10.1038/ncomms11883	10.1038/ncomms11883	27329137		6/13/19
MSH2												Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD						1		Guideline	"Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy."		Guideline	"National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf		20498393		11/3/17
MSH2												Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	1				Clinical evidence	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.		Journal	"Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20."	https://doi.org/10.1056/NEJMoa1500596	10.1056/NEJMoa1500596	26028255	NCT01876511	2/4/19
MSH6												Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD						1		Guideline	"Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy."		Guideline	"National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf		20498393		11/3/17
MSH6												Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	1				Clinical evidence	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.		Journal	"Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20."	https://doi.org/10.1056/NEJMoa1500596	10.1056/NEJMoa1500596	26028255	NCT01876511	2/4/19
NF1												Any solid tumor		Any solid tumor		Radiation therapy	Radiation	Radiation therapy				1	Clinical evidence	"Germline variants in genes known to cause cancer syndromes, such as TP53, RB1, and NF1, can increase the risk of radiation-induced secondary malignancies."		Journal	Kleinerman RA. Radiation-sensitive genetically susceptible pediatric sub-populations Pediatr Radiol. 2008; 39(S1):27-31.	https://doi.org/10.1007/s00247-008-1015-6	10.1007/s00247-008-1015-6	19083227		9/12/19
PALB2												Ovarian Cancer	Primary	"Ovarian Cancer, Other"	OOVC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
PALB2												Ovarian Cancer	Primary	"Ovarian Cancer, Other"	OOVC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
PALB2												Peritoneal Carcinoma	Primary	Peritoneal Mesothelioma	PEMESO						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
PALB2												Peritoneal Carcinoma	Primary	Peritoneal Mesothelioma	PEMESO						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
PALB2												Fallopian Tube Carcinoma	Primary	Serous Ovarian Cancer	SOC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
PALB2												Fallopian Tube Carcinoma	Primary	Serous Ovarian Cancer	SOC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
PALB2												Pancreatic Cancer		Pancreatic Adenocarcinoma	PAAD	Platinum	Platinum-based chemotherapy	Chemotherapy	1				Clinical evidence	"When present alongside genomic instability, defined by a large number of structural variation events, the inactivation of DNA maintenance genes (BRCA1, BRCA2, PALB2) was associated with increased sensitivity to platinum therapy in pancreatic cancer patients. "		Journal	"Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015;518(7540):495-501."	https://doi.org/10.1038/nature14169	10.1038/nature14169	25719666		3/7/19
PALB2											1	Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD						0		Clinical evidence	Pathogenic germline variants in PALB2 may increase risk of acquiring CRC. Germline pathogenic variants in PALB2 were enriched in several large cohorts of CRC patients when the frequency of multiple DNA-repair genes was compared to that of ancestry-matched healthy patients.		Journal	"AlDubayan SH, Giannakis M, Moore ND, et al. Inherited DNA-Repair Defects in Colorectal Cancer The American Journal of Human Genetics. 2018; 102(3):401-414."	https://doi.org/10.1016/j.ajhg.2018.01.018	10.1016/j.ajhg.2018.01.018	29478780		4/16/19
PMS2												Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD						1		Guideline	"Patients with defects in DNA mismatch repair genes often have a favorable prognosis and a decreased likelihood of metastasis. These patients do not benefit from, and may be resistant to, 5-fluorouracil therapy."		Guideline	"National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016."	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf		20498393		11/3/17
POLE2	14	50117073	50117073	-	A	c.1406dup	p.L469Ffs*17	Frameshift	17	rs776517397		Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD						0		Clinical evidence	Mutation may indicate increased susceptibility to early-onset colorectal cancer.		Journal	"Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883."	https://doi.org/10.1038/ncomms11883	10.1038/ncomms11883	27329137		6/13/19
POT1	7	124464068	124464070	TTA	T	c.1851_1852del	p.D617Efs*9	Frameshift	19	rs758673417		Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD						0		Clinical evidence	Mutation may indicate increased susceptibility to early-onset colorectal cancer.		Journal	"Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883."	https://doi.org/10.1038/ncomms11883	10.1038/ncomms11883	27329137		6/13/19
POT1	7	124482937	124482937	G	A	c.1087C>T	p.R363*	Nonsense	13	rs756198077		Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD						0		Clinical evidence	Mutation may indicate increased susceptibility to early-onset colorectal cancer.		Journal	"Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883."	https://doi.org/10.1038/ncomms11883	10.1038/ncomms11883	27329137		6/13/19
POT1	7	124511000	124511000	-	A	c.224dup	p.N75Kfs*16	Frameshift	7			Colorectal Cancer		Colorectal Adenocarcinoma	COADREAD						0		Clinical evidence	Mutation may indicate increased susceptibility to early-onset colorectal cancer.		Journal	"Chubb D, Broderick P, Dobbins SE, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun. 2016;7:11883."	https://doi.org/10.1038/ncomms11883	10.1038/ncomms11883	27329137		6/13/19
RAD51C												Fallopian Tube Carcinoma	Primary	Serous Ovarian Cancer	SOC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
RAD51C												Ovarian Cancer	Primary	"Ovarian Cancer, Other"	OOVC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
RAD51C												Ovarian Cancer	Primary	"Ovarian Cancer, Other"	OOVC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
RAD51C												Peritoneal Carcinoma	Primary	Peritoneal Mesothelioma	PEMESO						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
RAD51C												Peritoneal Carcinoma	Primary	Peritoneal Mesothelioma	PEMESO						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
RAD51C												Fallopian Tube Carcinoma	Primary	Serous Ovarian Cancer	SOC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
RAD51D												Ovarian Cancer	Primary	"Ovarian Cancer, Other"	OOVC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
RAD51D												Ovarian Cancer	Primary	"Ovarian Cancer, Other"	OOVC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
RAD51D												Peritoneal Carcinoma	Primary	Peritoneal Mesothelioma	PEMESO						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
RAD51D												Peritoneal Carcinoma	Primary	Peritoneal Mesothelioma	PEMESO						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
RAD51D												Fallopian Tube Carcinoma	Primary	Serous Ovarian Cancer	SOC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
RAD51D												Fallopian Tube Carcinoma	Primary	Serous Ovarian Cancer	SOC						1		Inferential	"Germline homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas. Mutant cases also had better overall survival than wild type."		Journal	"Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75."	https://doi.org/10.1158/1078-0432.CCR-13-2287	10.1158/1078-0432.CCR-13-2287	24240112		11/3/17
RB1												Any solid tumor		Any solid tumor		Radiation therapy	Radiation	Radiation therapy				1	Clinical evidence	"Germline variants in genes known to cause cancer syndromes, such as TP53, RB1, and NF1, can increase the risk of radiation-induced secondary malignancies."		Journal	Kleinerman RA. Radiation-sensitive genetically susceptible pediatric sub-populations Pediatr Radiol. 2008; 39(S1):27-31.	https://doi.org/10.1007/s00247-008-1015-6	10.1007/s00247-008-1015-6	19083227		9/12/19
TP53												Any solid tumor		Any solid tumor		Radiation therapy	Radiation	Radiation therapy				1	Clinical evidence	"Germline variants in genes known to cause cancer syndromes, such as TP53, RB1, and NF1, can increase the risk of radiation-induced secondary malignancies."		Journal	Kleinerman RA. Radiation-sensitive genetically susceptible pediatric sub-populations Pediatr Radiol. 2008; 39(S1):27-31.	https://doi.org/10.1007/s00247-008-1015-6	10.1007/s00247-008-1015-6	19083227		9/12/19